Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MASI 
Masimo Corporation (MASI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: MASI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $187.57
1 Year Target Price $187.57
| 4 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.63% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.00B USD | Price to earnings Ratio - | 1Y Target Price 187.57 |
Price to earnings Ratio - | 1Y Target Price 187.57 | ||
Volume (30-day avg) 9 | Beta 1.28 | 52 Weeks Range 133.70 - 194.88 | Updated Date 10/16/2025 |
52 Weeks Range 133.70 - 194.88 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -21.32% | Operating Margin (TTM) 17.12% |
Management Effectiveness
Return on Assets (TTM) 1.84% | Return on Equity (TTM) -22.37% |
Valuation
Trailing PE - | Forward PE 40 | Enterprise Value 8426738792 | Price to Sales(TTM) 3.71 |
Enterprise Value 8426738792 | Price to Sales(TTM) 3.71 | ||
Enterprise Value to Revenue 3.91 | Enterprise Value to EBITDA 29.56 | Shares Outstanding 54324812 | Shares Floating 46458036 |
Shares Outstanding 54324812 | Shares Floating 46458036 | ||
Percent Insiders 5.99 | Percent Institutions 109.98 |
Upturn AI SWOT
Masimo Corporation
Company Overview
History and Background
Masimo Corporation was founded in 1989 by Joe Kiani. It initially focused on developing signal processing innovations to solve the limitations of pulse oximetry. Masimo introduced Signal Extraction Technology (SET) in 1995, which improved the accuracy of pulse oximetry even during motion and low perfusion. The company has since expanded its offerings to include a broad range of noninvasive monitoring technologies.
Core Business Areas
- Healthcare: Develops, manufactures, and markets a variety of noninvasive monitoring technologies, including pulse oximetry, capnography, and brain monitoring products. Primarily serves hospitals, clinics, and other healthcare providers.
- Home Automation: Through its acquisition of Sound United, Masimo expanded into the consumer audio and home automation market. Brands include Denon, Marantz, and Bowers & Wilkins.
Leadership and Structure
Joe Kiani is the Chairman and CEO. The company has a traditional corporate structure with functional departments such as R&D, Marketing, Sales, and Operations.
Top Products and Market Share
Key Offerings
- Product Name 1: Radical-7 Pulse CO-Oximeter: A versatile, noninvasive patient monitoring platform that measures multiple blood constituents. While specific market share data is difficult to ascertain, Masimo is a leading player in the pulse oximetry market, competing with Medtronic and Philips Healthcare. Competitors: Medtronic, Philips Healthcare.
- Product Name 2: Root Patient Monitoring and Connectivity Platform: A connectivity and monitoring hub to integrate different Masimo and third party technologies. Competitors include Philips IntelliVue and Dru00e4ger Infinity Acute Care System. Competitors: Philips, Dru00e4ger.
Market Dynamics
Industry Overview
The patient monitoring market is growing due to an aging population, increasing prevalence of chronic diseases, and technological advancements in monitoring devices. The home automation market is also growing but highly fragmented.
Positioning
Masimo is a technology leader in noninvasive patient monitoring. They have a strong reputation for innovation and accuracy. However, the Sound United acquisition introduces Masimo into a new and very competitive market.
Total Addressable Market (TAM)
The global patient monitoring market is estimated at around $30 billion. The home audio market is also substantial, but Masimo is a newer and smaller player in that space. It is hard to quantify the TAM because it has just entered the Home Automation area.
Upturn SWOT Analysis
Strengths
- Strong brand reputation for innovation and accuracy
- Extensive patent portfolio
- Established relationships with healthcare providers
- High market share in niche areas of patient monitoring
Weaknesses
- Dependence on the healthcare market
- Relatively high product prices
- Integration challenges with Sound United acquisition
Opportunities
- Expanding into emerging markets
- Developing new noninvasive monitoring technologies
- Leveraging data analytics to improve patient outcomes
- Growth in the home healthcare market
Threats
- Increasing competition from established medical device companies
- Price pressure from healthcare providers
- Regulatory changes in the healthcare industry
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Philips (PHG)
- GE HealthCare (GEHC)
Competitive Landscape
Masimo has a competitive advantage in noninvasive monitoring technologies due to its strong patent portfolio and reputation for innovation. However, it faces significant competition from larger, more diversified medical device companies.
Major Acquisitions
Sound United
- Year: 2022
- Acquisition Price (USD millions): 1025
- Strategic Rationale: To expand into the consumer audio and home automation market, diversifying its revenue streams.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the adoption of Masimo's SET technology and the expansion of its product portfolio.
Future Projections: Future growth is expected to come from new product launches, geographic expansion, and the integration of Sound United.
Recent Initiatives: Recent initiatives include the acquisition of Sound United, the launch of new monitoring technologies, and partnerships with other healthcare companies.
Summary
Masimo is a strong company with a solid reputation and innovative technology in the noninvasive patient monitoring field. Its acquisition of Sound United diversifies its portfolio but introduces new challenges in a different market. Masimo needs to successfully integrate Sound United and maintain its technological edge in patient monitoring to sustain long-term growth. Competition in both healthcare and consumer markets remains a key area to watch out for, along with market changes and consumer spending.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Market Research Reports
- Analyst Estimates
- Company Website
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Conduct thorough research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Masimo Corporation
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2007-08-08 | CEO & Director Ms. Catherine M. Szyman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3600 | Website https://www.masimo.com |
Full time employees 3600 | Website https://www.masimo.com | ||
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, methemoglobin, hemoglobin, fractional arterial oxygen saturation, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow respiratory support therapy, neuromodulation technology, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.